Pfizer Corporation

Nandini Chaturbhai Patel

Patrick Robert Verhoest

Thomas Allen Chappie

Simone Sciabola

Christopher John Helal

Matthew Merrill Hayward

Erik Alphie LaChapelle

Travis T Wager

Joseph Michael Young

Erik Alphie Lachapelle

Chakrapani Subramanyam

Christopher John O'Donnell

Michael Eric Green

Martin Youngjin Pettersson

Douglas Scott Johnson

Antonia Friederike Stepan

Tuan Phong Tran

Christopher William Am Ende

Cory Michael Stiff

Gregory Wayne Kauffman

Jaclyn Louise Henderson

Bethany Lyn Kormos

Jamison Bryce Tuttle

Ramalakshmi Yegna Chandrasekaran

Joseph Walter Tucker

Christopher John O'donnell

Susan Deborah Lagreca

Travis T Wagner

John Charles Kath

Michael Joseph Luzzio

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R, R, R, R, R, Rand n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

Tricyclic compounds and their use as phosphodiesterase inhibitors

The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression. 

6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands

The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds. 

6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, R, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

Imidazopyridazine compounds

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

The present invention is directed to pyrazolopyrimine compounds or pharmaceutically acceptable salts which are inhibitors of PDE4 isozymes, especially with a binding affinity for PDE4B isoform, and compositions thereof.

Pyrazolopyrimidine compounds

The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.

Azabenzimidazole compounds

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders

Growing community of inventors

Waban, MA, United States of America

Nandini Chaturbhai Patel